Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

A Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results.

Eric D. Jacobsen, MD, Ranjana H. Advani, MD, Yasuhiro Oki, MD, Jeff Sharman, MD, Steven M. Horwitz, MD, Andres Forero-Torres, MD, Owen A. O'Connor, MD, PhD, Andrei R. Shustov, MD, Tanya Siddiqi, MD, Laurie E. Grove, PA-C, Nancy L. Bartlett, MD

Blood (2012) 120 (21): 2746.

https://doi.org/10.1182/blood.V120.21.2746.2746

Published: 2012

Journal Articles

Brentuximab Vedotin (SGN-35) Enables Successful Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Relapsed/Refractory Hodgkin Lymphoma

Robert W. Chen, MD, Stephen J. Forman, MD, Joycelynne Palmer, PhD, Ni-Chun Tsai, MS, Leslie Popplewell, MD, Maria L Delioukina, MD, Torres Alejandra, MS, Bernadette Pulone, RN, OCN, Eileen P. Smith, MD, Auayporn P. Nademanee, MD, Chatchada Karanes, MD, Paul O'Donnell, MD, PhD, David G. Maloney, MD, PhD, Len Farol, MD, Schickwann Tsai, MD, PhD, Laurie E. Grove, PA-C, Ajay K. Gopal, MD

Blood (2011) 118 (21): 664.

https://doi.org/10.1182/blood.V118.21.664.664

Published: 2011

Journal Articles

Allogeneic Transplant Following Brentuximab Vedotin Treatment in Patients with Relapsed or Refractory CD30+ Lymphomas

Tim Illidge, Reda Bouabdallah, MD, Robert W. Chen, MD, Ajay K. Gopal, MD, Craig H. Moskowitz, MD, Radhakrishnan Ramchandren, Joseph D. Rosenblatt, MD, Andrei R. Shustov, MD, Herve Tilly, MD, Tanya Trippett, MD, Laurie E. Grove, PA-C, Ranjana H. Advani, MD

Blood (2011) 118 (21): 3091.

https://doi.org/10.1182/blood.V118.21.3091.3091

Published: 2011

Journal Articles

Prolonged Treatment with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL),

Andres Forero-Torres, MD, R. Brian Berryman, MD, Ranjana H. Advani, MD, Nancy L. Bartlett, MD, Robert W. Chen, MD, Michelle A. Fanale, MD, Ajay K. Gopal, MD, Owen A. O'Connor, MD, PhD, Randal Olshefski, MD, Scott E. Smith, MD, PhD, FACP, Laurie E. Grove, PA-C, Jeffrey Matous, MD

Blood (2011) 118 (21): 3711.

https://doi.org/10.1182/blood.V118.21.3711.3711

Published: 2011

Journal Articles

Lintuzumab and Low-Dose Cytarabine Compared to Placebo and Low-Dose Cytarabine in Patients with Untreated Acute Myeloid Leukemia (AML) 60 Years and Older: Results of a Randomized, Double-Blinded Phase 2b Study,

Jeffrey E. Lancet, MD, Mikkael A. Sekeres, MD, MS, Brent L. Wood, MD, PhD, Laurie E. Grove, PA-C, Larissa Sandalic, MS, Eric L. Sievers, MD, Joseph G. Jurcic, MD

Blood (2011) 118 (21): 3613.

https://doi.org/10.1182/blood.V118.21.3613.3613

Published: 2011

Journal Articles

Complete Remissions Observed in Acute Myeloid Leukemia Following Prolonged Exposure to SGN-33 (lintuzumab), a Humanized Monoclonal Antibody Targeting CD33.

Azra Raza, MD, Joseph G. Jurcic, MD, Gail J. Roboz, MD, Michael Maris, MD, Joseph Stephenson, MD, Brent L. Wood, MD, Bhaskar Rege, PhD, Laurie E. Grove, PA-C, Jonathan G. Drachman, MD, Eric L. Sievers, MD

Blood (2007) 110 (11): 159.

https://doi.org/10.1182/blood.V110.11.159.159

Published: 2007

Journal Articles

Increased Dose Intensity of SGN-33, a Humanized Monoclonal Antibody Targeting CD33, Is Active and Well-Tolerated in Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS).

Azra Raza, MD, Joseph G. Jurcic, MD, Gail J. Roboz, MD, Joseph J. Stephenson, MD, Mark U. Rarick, MD, Brent L. Wood, MD, Laurie E. Grove, PA-C, Eric L. Sievers, MD, Jonathan G. Drachman, MD

Blood (2006) 108 (11): 4568.

https://doi.org/10.1182/blood.V108.11.4568.4568

Published: 2006

NARROW

A Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results.

Brentuximab Vedotin (SGN-35) Enables Successful Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Relapsed/Refractory Hodgkin Lymphoma

Allogeneic Transplant Following Brentuximab Vedotin Treatment in Patients with Relapsed or Refractory CD30+ Lymphomas

Prolonged Treatment with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL),

Lintuzumab and Low-Dose Cytarabine Compared to Placebo and Low-Dose Cytarabine in Patients with Untreated Acute Myeloid Leukemia (AML) 60 Years and Older: Results of a Randomized, Double-Blinded Phase 2b Study,

Complete Remissions Observed in Acute Myeloid Leukemia Following Prolonged Exposure to SGN-33 (lintuzumab), a Humanized Monoclonal Antibody Targeting CD33.

Increased Dose Intensity of SGN-33, a Humanized Monoclonal Antibody Targeting CD33, Is Active and Well-Tolerated in Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS).

Email alerts

ASH Publications

American Society of Hematology

A Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results.

Brentuximab Vedotin (SGN-35) Enables Successful Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Relapsed/Refractory Hodgkin Lymphoma

Allogeneic Transplant Following Brentuximab Vedotin Treatment in Patients with Relapsed or Refractory CD30+ Lymphomas

Prolonged Treatment with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL),

Lintuzumab and Low-Dose Cytarabine Compared to Placebo and Low-Dose Cytarabine in Patients with Untreated Acute Myeloid Leukemia (AML) 60 Years and Older: Results of a Randomized, Double-Blinded Phase 2b Study,

Complete Remissions Observed in Acute Myeloid Leukemia Following Prolonged Exposure to SGN-33 (lintuzumab), a Humanized Monoclonal Antibody Targeting CD33.

Increased Dose Intensity of SGN-33, a Humanized Monoclonal Antibody Targeting CD33, Is Active and Well-Tolerated in Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only